InnoCare Pharma Limited

Research InnoCare Pharma Limited (9969.HK) on Bullrun: market cap HKD 21.77B, P/E 20.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker9969.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 21.77B
P/E20.5
Financial periodFY2025
RevenueCNY 2.37B
Revenue growth135.3%
Net incomeCNY 642.47M
Free cash flowCNY 13.77M
Gross margin92.0%

Valuation Snapshot

latest market cap is HKD 21.77B; P/E is 20.5.

Peer valuation comparison

Latest P/E is 20.53x versus a Healthcare sector median of 21.69x (5.3% below).

Latest P/E is 20.53x versus a China median of 16.26x (26.3% above).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 2.37B	CNY 642.47M	CNY 13.77M	92.0%	0.38	CNY 7.05B	CNY 1.29B	CNY 7.73B
FY2024	CNY 1.01B	-CNY 440.63M	-CNY 443.78M	86.3%	-0.26	CNY 6.22B	CNY 1.27B	CNY 6.73B
FY2023	CNY 738.54M	-CNY 631.26M	-CNY 926.00M	82.6%	-0.37	CNY 8.22B	CNY 1.35B	CNY 7.15B
FY2022	CNY 625.40M	-CNY 886.59M	-CNY 935.88M	77.1%	-0.6	CNY 8.70B	CNY 1.25B	CNY 7.60B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 21.77B	20.5	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About InnoCare Pharma Limited

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is InnoCare Pharma Limited's market cap?

InnoCare Pharma Limited's market capitalization is HKD 21.77B.

What is InnoCare Pharma Limited's P/E ratio?

InnoCare Pharma Limited's price-to-earnings (P/E) ratio is 20.5.

What does InnoCare Pharma Limited do?

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.